1-15 of 15
Antoine Hollebecque
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies

Francesco Facchinetti, Yohann Loriot, Floriane Brayé, Damien Vasseur, Rastislav Bahleda, Ludovic Bigot, Rémy Barbé, Catline Nobre, David Combarel, Stefan Michiels, Antoine Italiano, Cristina Smolenschi, Lambros Tselikas, Jean-Yves Scoazec, Santiago Ponce-Aix, Benjamin Besse, Fabrice André, Ken A. Olaussen, Antoine Hollebecque, Luc Friboulet
Journal: Clinical Cancer Research
Clin Cancer Res OF1–OF14.
https://doi.org/10.1158/1078-0432.CCR-24-1834
Published: 09 October 2024
View article titled, Understanding and Overcoming Resistance to Selective FGFR Inhibitors across <em>FGFR2</em>-Driven Malignancies
Open the PDF for Understanding and Overcoming Resistance to Selective FGFR Inhibitors across <em>FGFR2</em>-Driven Malignancies in another window
Includes: Supplementary data
Journal Articles

Safety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1–4 Inhibitor: Pooled Safety Analysis of 469 Patients

Funda Meric-Bernstam, Antoine Hollebecque, Junji Furuse, Do-Youn Oh, John A. Bridgewater, Masashi Shimura, Bailey Anderson, Nanae Hangai, Volker Wacheck, Lipika Goyal
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (8): 1466–1477.
https://doi.org/10.1158/1078-0432.CCR-23-2646
Published: 15 April 2024
View article titled, Safety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1–4 Inhibitor: Pooled Safety Analysis of 469 Patients
Open the PDF for Safety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1–4 Inhibitor: Pooled Safety Analysis of 469 Patients in another window
Includes: Supplementary data
Journal Articles

Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability–High/Mismatch Repair–Deficient Tumors

Antoine Hollebecque, Hyun C. Chung, Maria J. de Miguel, Antoine Italiano, Jean-Pascal Machiels, Chia-Chi Lin, Neesha C. Dhani, Marc Peeters, Victor Moreno, Wu-Chou Su, Kay Hoong Chow, Violeta R. Galvao, Michelle Carlsen, Danni Yu, Anna M. Szpurka, Yumin Zhao, Shelly L. Schmidt, Leena Gandhi, Xiaojian Xu, Yung-Jue Bang
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (23): 6393–6404.
https://doi.org/10.1158/1078-0432.CCR-21-0261
Published: 01 December 2021
View article titled, Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability–High/Mismatch Repair–Deficient Tumors
Open the PDF for Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability–High/Mismatch Repair–Deficient Tumors in another window
Includes: Supplementary data
Journal Articles

First-in-Human Phase I Study of ABBV-085, an Antibody–Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors

George D. Demetri, Jason J. Luke, Antoine Hollebecque, John D. Powderly, II, Alexander I. Spira, Vivek Subbiah, Louie Naumovski, Chris Chen, Hua Fang, Dominic W. Lai, Huibin Yue, Akshanth R. Polepally, James W. Purcell, Randy Robinson, Padmanee Sharma, James P. Allison, Anthony Tolcher, Victor M. Villalobos
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (13): 3556–3566.
https://doi.org/10.1158/1078-0432.CCR-20-4513
Published: 01 July 2021
View article titled, First-in-Human Phase I Study of ABBV-085, an Antibody–Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors
Open the PDF for First-in-Human Phase I Study of ABBV-085, an Antibody–Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma

Antoine Hollebecque, Stefania Salvagni, Ruth Plummer, Nicolas Isambert, Patricia Niccoli, Jaume Capdevila, Giuseppe Curigliano, Victor Moreno, Patricia Martin-Romano, Eric Baudin, Marina Arias, Sheila Mora, Juan de Alvaro, Jorge Di Martino, Josep L. Parra-Palau, Tania Sánchez-Pérez, Ida Aronchik, Ellen H. Filvaroff, Manisha Lamba, Zariana Nikolova, Johann S. de Bono
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (2): 438–446.
https://doi.org/10.1158/1078-0432.CCR-20-2380
Published: 19 January 2021
View article titled, Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma
Open the PDF for Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma in another window
Includes: Supplementary data
Journal Articles

BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer

Gary Middleton, Yiqun Yang, Catarina D. Campbell, Thierry André, Chloe E. Atreya, Jan H.M. Schellens, Takayuki Yoshino, Johanna C. Bendell, Antoine Hollebecque, Autumn J. McRee, Salvatore Siena, Michael S. Gordon, Josep Tabernero, Rona Yaeger, Peter J. O'Dwyer, Filip De Vos, Eric Van Cutsem, John M. Millholland, Jan C. Brase, Fatima Rangwala, Eduard Gasal, Ryan B. Corcoran
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (11): 2466–2476.
https://doi.org/10.1158/1078-0432.CCR-19-3579
Published: 01 June 2020
View article titled, <em>BRAF</em>-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer
Open the PDF for <em>BRAF</em>-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors

Andrea Varga, Jean-Charles Soria, Antoine Hollebecque, Patricia LoRusso, Johanna Bendell, Shih-Min A. Huang, Marie-Claire Wagle, Kwame Okrah, Lichuan Liu, Elaine Murray, Sandra M. Sanabria-Bohorquez, Michael Tagen, Hatem Dokainish, Lars Mueller, Howard Burris
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (6): 1229–1236.
https://doi.org/10.1158/1078-0432.CCR-19-2574
Published: 13 March 2020
View article titled, A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors
Open the PDF for A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors

Francesco Facchinetti, Antoine Hollebecque, Rastislav Bahleda, Yohann Loriot, Ken A. Olaussen, Christophe Massard, Luc Friboulet
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (4): 764–774.
https://doi.org/10.1158/1078-0432.CCR-19-2035
Published: 14 February 2020
View article titled, Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors
Open the PDF for Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer

Gonzalo Recondo, Laura Mezquita, Francesco Facchinetti, David Planchard, Anas Gazzah, Ludovic Bigot, Ahsan Z. Rizvi, Rosa L. Frias, Jean Paul Thiery, Jean-Yves Scoazec, Tony Sourisseau, Karen Howarth, Olivier Deas, Dariia Samofalova, Justine Galissant, Pauline Tesson, Floriane Braye, Charles Naltet, Pernelle Lavaud, Linda Mahjoubi, Aurélie Abou Lovergne, Gilles Vassal, Rastilav Bahleda, Antoine Hollebecque, Claudio Nicotra, Maud Ngo-Camus, Stefan Michiels, Ludovic Lacroix, Catherine Richon, Nathalie Auger, Thierry De Baere, Lambros Tselikas, Eric Solary, Eric Angevin, Alexander M. Eggermont, Fabrice Andre, Christophe Massard, Ken A. Olaussen, Jean-Charles Soria, Benjamin Besse, Luc Friboulet
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (1): 242–255.
https://doi.org/10.1158/1078-0432.CCR-19-1104
Published: 03 January 2020
View article titled, Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer
Open the PDF for Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Long-Term Survival in Patients Responding to Anti–PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation

Marie-Léa Gauci, Emilie Lanoy, Stéphane Champiat, Caroline Caramella, Samy Ammari, Sandrine Aspeslagh, Andrea Varga, Capucine Baldini, Rastilav Bahleda, Anas Gazzah, Jean-Marie Michot, Sophie Postel-Vinay, Eric Angevin, Vincent Ribrag, Antoine Hollebecque, Jean-Charles Soria, Caroline Robert, Christophe Massard, Aurélien Marabelle
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (3): 946–956.
https://doi.org/10.1158/1078-0432.CCR-18-0793
Published: 01 February 2019
View article titled, Long-Term Survival in Patients Responding to Anti–PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation
Open the PDF for Long-Term Survival in Patients Responding to Anti–PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation in another window
Includes: Supplementary data
Journal Articles

Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors

Jeffrey R. Infante, Antoine Hollebecque, Sophie Postel-Vinay, Todd M. Bauer, Elizabeth M. Blackwood, Marie Evangelista, Sami Mahrus, Franklin V. Peale, Xuyang Lu, Srikumar Sahasranaman, Rui Zhu, Yuan Chen, Xiao Ding, Elaine R. Murray, Jennifer L. Schutzman, Jennifer O. Lauchle, Jean-Charles Soria, Patricia M. LoRusso
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (10): 2423–2432.
https://doi.org/10.1158/1078-0432.CCR-16-1782
Published: 14 May 2017
View article titled, Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors
Open the PDF for Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1

Stéphane Champiat, Laurent Dercle, Samy Ammari, Christophe Massard, Antoine Hollebecque, Sophie Postel-Vinay, Nathalie Chaput, Alexander Eggermont, Aurélien Marabelle, Jean-Charles Soria, Charles Ferté
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (8): 1920–1928.
https://doi.org/10.1158/1078-0432.CCR-16-1741
Published: 13 April 2017
View article titled, Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
Open the PDF for Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1 in another window
Includes: Supplementary data
Journal Articles

Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial

Cécile Jovelet, Ecaterina Ileana, Marie-Cécile Le Deley, Nelly Motté, Silvia Rosellini, Alfredo Romero, Celine Lefebvre, Marion Pedrero, Noémie Pata-Merci, Nathalie Droin, Marc Deloger, Christophe Massard, Antoine Hollebecque, Charles Ferté, Amélie Boichard, Sophie Postel-Vinay, Maud Ngo-Camus, Thierry De Baere, Philippe Vielh, Jean-Yves Scoazec, Gilles Vassal, Alexander Eggermont, Fabrice André, Jean-Charles Soria, Ludovic Lacroix
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (12): 2960–2968.
https://doi.org/10.1158/1078-0432.CCR-15-2470
Published: 14 June 2016
View article titled, Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial
Open the PDF for Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial in another window
Includes: Supplementary data
Journal Articles

A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies

Shilpa Gupta, Guillem Argilés, Pamela N. Munster, Antoine Hollebecque, Olav Dajani, Jonathan D. Cheng, Ruixue Wang, Ann Swift, Alessandra Tosolini, Sarina A. Piha-Paul
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (23): 5235–5244.
https://doi.org/10.1158/1078-0432.CCR-15-0180
Published: 30 November 2015
View article titled, A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies
Open the PDF for A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies in another window
Includes: Supplementary data
Journal Articles

Tumor Growth Rate Is an Early Indicator of Antitumor Drug Activity in Phase I Clinical Trials

Charles Ferté, Marianna Fernandez, Antoine Hollebecque, Serge Koscielny, Antonin Levy, Christophe Massard, Rastislav Balheda, Brian Bot, Carlos Gomez-Roca, Clarisse Dromain, Samy Ammari, Jean-Charles Soria
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (1): 246–252.
https://doi.org/10.1158/1078-0432.CCR-13-2098
Published: 05 January 2014
View article titled, Tumor Growth Rate Is an Early Indicator of Antitumor Drug Activity in Phase I Clinical Trials
Open the PDF for Tumor Growth Rate Is an Early Indicator of Antitumor Drug Activity in Phase I Clinical Trials in another window
Includes: Supplementary data